Bisphosphonates regulate cell proliferation, apoptosis and pro-osteoclastic expression in MG‑63 human osteosarcoma cells

Chang,Jun; Wang,Wei; Zhang,Hui; Hu,Yong; Yin,Zongsheng

doi:10.3892/ol.2012.723

Bisphosphonates regulate cell proliferation, apoptosis and pro-osteoclastic expression in MG‑63 human osteosarcoma cells

Authors:
- Jun Chang
- Wei Wang
- Hui Zhang
- Yong Hu
- Zongsheng Yin
View Affiliations

Affiliations: Department of Orthopaedics, First Affiliated Hospital, Anhui Medical University, Hefei, Anhui 230022, P.R. China
Published online on: May 21, 2012 https://doi.org/10.3892/ol.2012.723
Pages: 299-304

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Bisphosphonates are well established in the management of cancer-induced skeletal complications. Recent studies suggest that nitrogen-containing bisphosphonates (N-BPs) promote the apoptosis of cancer cells as well as osteoclasts in bone metastatic sites. To investigate whether N-BPs exhibit a direct antitumor effect on osteoclasts, the current study investigated the effects of zoledronic acid (ZOL) on MG-63 cells in vitro. MG-63 cells were treated with ZOL. The inhibitory effect of ZOL on the growth of MG-63 cells was measured by MTT assay. ZOL-induced apoptosis of the MG-63 cells was examined by Hoechst 33258 staining, electron microscopy, Annexin V-FITC and propidium iodide staining. Reverse-transcription polymerase chain reaction (RT-PCR) and western blotting analysis were employed to assess the expression of osteoprotegerin (OPG) and receptor activator of nuclear factor-κB ligand (RANKL). The MTT assay showed that ZOL induced a distinct dose- and time‑dependent reduction of cell viability with an IC50 value of 52.37±1.0 µM for 72 h. Flow cytometric analysis further revealed that the cell apoptosis was induced by arrest of the cell cycle in the G1 phase. RT-PCR and western blot analysis demonstrated that ZOL upregulated OPG expression. These results suggest that ZOL has direct effects on osteosarcoma cell growth and apoptosis. Increased OPG expression is an indirect effect, possibly via changes in the local microenvironment.

View Figures

View References

1	Bacci G, Longhi A, Fagioli F, Briccoli A, Versari M and Picci P: Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli Institute, Italy. Eur J Cancer. 41:2836–2845. 2005.PubMed/NCBI
2	Perry CM and Figgitt DP: Zoledronic acid: a review of its use in patients with advanced cancer. Drugs. 64:1197–1211. 2004. View Article : Google Scholar : PubMed/NCBI
3	Green JR: Skeletal complications of prostate cancer: pathophysiology and therapeutic potential of bisphosphonates. Acta Oncol. 44:282–292. 2005. View Article : Google Scholar : PubMed/NCBI
4	Baulch-Brown C, Molloy TJ, Yeh SL, Ma D and Spencer A: Inhibitors of the mevalonate pathway as potential therapeutic agents in multiple myeloma. Leuk Res. 31:341–352. 2007. View Article : Google Scholar : PubMed/NCBI
5	Iguchi K, Nakano T, Usui S and Hirano K: Incadronate inhibits aminopeptidase N expression in prostatic PC-3 cells. Cancer Lett. 237:223–233. 2006. View Article : Google Scholar : PubMed/NCBI
6	Nakajima H, Magae J, Tsuruga M, Sakaguchi K, Fujiwara I, Mizuta M, Sawai K, Yamagishi H and Mizuta N: Induction of mitochondria-dependent apoptosis through the inhibition of mevalonate pathway in human breast cancer cells by YM529, a new third generation bisphosphonate. Cancer Lett. 253:89–96. 2007. View Article : Google Scholar
7	Tassone P, Tagliaferri P, Viscomi C, Palmieri C, Caraglia M, D’Alessandro A, Galea E, Goel A, Abbruzzese A, Boland CR and Venuta S: Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro. Br J Cancer. 88:1971–1978. 2003. View Article : Google Scholar : PubMed/NCBI
8	Im GI, Qureshi SA, Kenney J, Rubash HE and Shanbhag AS: Osteoblast proliferation and maturation by bisphosphonates. Biomaterials. 25:4105–4115. 2004. View Article : Google Scholar : PubMed/NCBI
9	Viereck V, Emons G, Lauck V, Frosch KH, Blaschke S, Gründker C and Hofbauer LC: Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun. 291:680–686. 2002. View Article : Google Scholar : PubMed/NCBI
10	Wittrant Y, Théoleyre S, Chipoy C, Padrines M, Blanchard F, Heymann D and Rédini F: RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. Biochim Biophys Acta. 1704:49–57. 2004.PubMed/NCBI
11	Dougall WC and Chaisson M: The RANK/RANKL/OPG triad in cancer-induced bone diseases. Cancer Metastasis Rev. 25:541–549. 2006. View Article : Google Scholar : PubMed/NCBI
12	Baud’huin M, Duplomb L, Ruiz Velasco C, Fortun Y, Heymann D and Padrines M: Key roles of the OPG-RANK-RANKL system in bone oncology. Expert Rev Anticancer Ther. 7:221–232. 2007.PubMed/NCBI
13	Plotkin LI, Manolagas SC and Bellido T: Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs. Bone. 39:443–452. 2006. View Article : Google Scholar : PubMed/NCBI
14	Green JR: Antitumor effects of bisphosphonates. Cancer. 97:840–847. 2003. View Article : Google Scholar : PubMed/NCBI
15	Horie N, Murata H, Nishigaki Y, Matsui T, Segawa H, Nogawa M, Yuasa T, Kimura S, Maekawa T, Fushiki S and Kubo T: The third-generation bisphosphonates inhibit proliferation of murine osteosarcoma cells with induction of apoptosis. Cancer Lett. 238:111–118. 2006. View Article : Google Scholar : PubMed/NCBI
16	Koshimune R, Aoe M, Toyooka S, Hara F, Ouchida M, Tokumo M, Sano Y, Date H and Shimizu N: Anti-tumor effect of bisphosphonate (YM529) on non-small cell lung cancer cell lines. BMC Cancer. 7:82007. View Article : Google Scholar : PubMed/NCBI
17	Dickson PV, Hamner JB, Cauthen LA, Ng CY, McCarville MB and Davidoff AM: Efficacy of zoledronate against neuroblastoma. Surgery. 140:227–235. 2006. View Article : Google Scholar : PubMed/NCBI
18	Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH and Rogers MJ: Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 296:235–242. 2001.
19	Ishikawa C, Matsuda T, Okudaira T, Tomita M, Kawakami H, Tanaka Y, Masuda M, Ohshiro K, Ohta T and Mori N: Bisphosphonate incadronate inhibits growth of human T-cell leukaemia virus type I-infected T-cell lines and primary adult T-cell leukaemia cells by interfering with the mevalonate pathway. Br J Haematol. 136:424–432. 2007. View Article : Google Scholar
20	Caraglia M, Santini D, Marra M, Vincenzi B, Tonini G and Budillon A: Emerging anti-cancer molecular mechanisms of aminobisphosphonates. Endocr Relat Cancer. 13:7–26. 2006. View Article : Google Scholar : PubMed/NCBI
21	Ory B, Blanchard F, Battaglia S, Gouin F, Rédini F and Heymann D: Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation independently of p53 and retinoblastoma status. Mol Pharmacol. 71:333–343. 2007. View Article : Google Scholar
22	Mori K, Le Goff B, Berreur M, Riet A, Moreau A, Blanchard F, Chevalier C, Guisle-Marsollier I, Léger J, Guicheux J, et al: Human osteosarcoma cells express functional receptor activator of nuclear factor-kappa B. J Pathol. 211:555–562. 2007. View Article : Google Scholar : PubMed/NCBI
23	Benassi MS, Chiechi A, Ponticelli F, Pazzaglia L, Gamberi G, Zanella L, Manara MC, Perego P, Ferrari S and Picci P: Growth inhibition and sensitization to cisplatin by zoledronic acid in osteosarcoma cells. Cancer Lett. 250:194–205. 2007. View Article : Google Scholar : PubMed/NCBI
24	Zhang J, Dai J, Qi Y, Lin DL, Smith P, Strayhorn C, Mizokami A, Fu Z, Westman J and Keller ET: Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest. 107:1235–1244. 2001. View Article : Google Scholar : PubMed/NCBI
25	Ishii R, Morimoto A, Ikushima S, Sugimoto T, Asami K, Bessho F, Kudo K, Tsunematu Y, Fujimoto J and Imashuku S: High serum values of soluble CD154, IL-2 receptor, RANKL and osteoprotegerin in Langerhans cell histiocytosis. Pediatr Blood Cancer. 47:194–199. 2006. View Article : Google Scholar : PubMed/NCBI
26	Mintz MB, Sowers R, Brown KM, Hilmer SC, Mazza B, Huvos AG, Meyers PA, Lafleur B, McDonough WS, Henry MM, et al: An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. Cancer Res. 65:1748–1754. 2005. View Article : Google Scholar : PubMed/NCBI
27	Grimaud E, Soubigou L, Couillaud S, Coipeau P, Moreau A, Passuti N, Gouin F, Redini F and Heymann D: Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. Am J Pathol. 163:2021–2031. 2003. View Article : Google Scholar : PubMed/NCBI
28	Quinn JE, Brown LG, Zhang J, Keller ET, Vessella RL and Corey E: Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms. Prostate Cancer Prostatic Dis. 8:253–259. 2005. View Article : Google Scholar : PubMed/NCBI
29	Tannehill-Gregg SH, Levine AL, Nadella MV, Iguchi H and Rosol TJ: The effect of zoledronic acid and osteoprotegerin on growth of human lung cancer in the tibias of nude mice. Clin Exp Metastasis. 23:19–31. 2006. View Article : Google Scholar : PubMed/NCBI
30	Zheng Y, Zhou H, Brennan K, Blair JM, Modzelewski JR, Seibel MJ and Dunstan CR: Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis. Bone. 40:471–478. 2007. View Article : Google Scholar : PubMed/NCBI